Liven Pharma Limited LIVEN
Rs 29.11
Vol34,892Updated15:492 Nov 2026
At a Glance
The headline take on LIVEN — valuation, income, returns, and efficiency
Consolidated snapshot
Price & Performance
Closing prices across timeframes, returns, and range context
LIVEN — Price History
Daily closing series · toggle period below
Key Metrics
Valuation, profitability, structure, and risk in one grid
Dividend History & Yield
Payout track record, yield trend, and upcoming distribution
LIVEN has no cash dividend in the trailing 12 months. Its most recent payout was a 21.496% rights issue, announced 12 Sep 2025 with book closure from 27 Nov 2025.
Latest Payout
Dividend Per Share Trend
Not enough history for a trend yet — see the payout table below.
Payout History
Source: PSX company payouts
| Announced | For Period | Type | Amount | Book Closure |
|---|---|---|---|---|
| 12 Sep 2025 | — | Rights | 21.496% | 27 Nov 2025 – 27 Nov 2025 |
Financials & Earnings
Income, balance sheet, and key ratios from published accounts
LIVEN's market capitalisation stands at Rs 3.30B as of 02 Nov 2026 — down 52.6% over the past 12 months (from Rs 6.97B).
Financial Statements
How LIVEN's income and balance sheet have evolved
| PKR Millions | FY26 | FY25 | Trend |
|---|---|---|---|
| Net Sales / Revenue | 105.81 | 127.27 | |
| Cost of Sales | 79.16 | 109.31 | |
| Gross Profit | 26.65 | 17.96 | |
| Administrative Expenses | 37.71 | 373.56 | |
| Operating Profit | -77.14 | -490.9 | |
| Other Income | 12.22 | 0.31 | |
| Financial Charges | 2.54 | 0.79 | |
| Profit Before Tax | -64.92 | -490.6 | |
| Taxation | 33.78 | 93.86 | |
| Profit After Tax | -31.14 | -584.46 | |
| EPS - Basic (Rs) | Rs -0.28 | Rs -7.11 |
All figures in PKR millions from published accounts · quarterly statements not yet available for this company.
Profitability & Returns
Margins, returns on capital, and earnings per share
Latest · FY26
| Ratio | Value |
|---|---|
| Net profit margin | -29.4% |
| Gross profit margin | 25.2% |
| EBIT margin | -72.9% |
Net profit margin
Net profit ÷ revenue · %
Financial Health
Coverage, leverage, and the strength of the balance sheet
Latest · FY26
| Ratio | Value |
|---|---|
| Current ratio | 2.63 |
| Quick ratio | 1.73 |
| Cash ratio | 1.63 |
| Asset turnover | 0.09x |
Current ratio
Current assets ÷ current liabilities
Market cap trajectory
Close × current shares outstanding · current Rs 3.30B
Valuation & Capital Returns
What the market is paying for LIVEN, and what it returns to shareholders
Latest · FY26
| Ratio | Value |
|---|---|
| Price to book | 3.35x |
| Price to sales | 31.20x |
Price to book
Period-end price ÷ book value · times
Technical Analysis
Trading signal, moving averages, momentum, and key levels
10-day SMA (Rs 30.58) is below the 30-day SMA (Rs 30.98). RSI at 36 sits in the neutral band.
Moving AverageThe average close over a set window (10/30/200 days) — smooths daily noise to reveal the trend.Read the full guide →
| Period | Value | vs Current | Position |
|---|---|---|---|
| SMA 10 | Rs 30.58 | +5.05% | Below |
| SMA 30 | Rs 30.98 | +6.42% | Below |
| SMA 60 | Rs 32.14 | +10.39% | Below |
| SMA 200 | Rs 37.15 | +27.62% | Below |
At 36, momentum sits within the neutral band (30–70), suggesting balanced buying and selling pressure.
- MACD-0.42
- Signal-0.35
- Histogram-0.08
Leverage Insights
MTS, margin financing, futures open interest, and combined exposure
Leverage Composition
MTS · MFS stacked over the selected window
No blank sales
No net blank (short) sales reported for LIVEN on the latest PSX DFC report.
Settlement Insights
UIN-wise settlement concentration and price context
Metrics and charts over the selected trailing window
Settlement % Trajectory
Solid = UIN settlement % · Dashed = 14-session EMA
As of 30 Oct 2026
Price vs Settlement
Close price (left axis) · UIN settlement % (right axis)
About the Company
Business description, governance, and corporate information
Liven Pharma Limited was incorporated in Pakistan as a private Limited Company on October 21, 1991 and was converted into a public limited company on April 30, 1992 under the Companies Ordinance, 1984 (Repealed with the enactment of the Companies Act, 2017). The principal activity of the Company is the manufacturing of pharmaceuticals and allied products.
Corporate Information
- RegistrarF.D. Registrar Services SMC (Pvt.) Ltd., 1705,17th Floor, Saima Trade Tower A, I.I. Chundrigar Road, Karachi
- AuditorM/s Reanda Haroon Zakaria Aamir Salman Rizwan & Company, Chartered Accountants
- Websitewww.liven-pharma.com
- Address49-Km, Multan Road, Lahore
- SectorPharmaceuticals
- Financial Year EndJune
Key People
| Name | Role |
|---|---|
KHKashif Hussain Siddiquie | CEO |
AHAtif Hussain Siddiqi | Chairman |
MSMuhammad Saeed | Company Secretary |
Reports & Filings
- Annual Report FY2026PDF
- Quarterly Report — 31 Dec 2025PDF
- Quarterly Report — 31 Dec 2025PDF
- Quarterly Report — 31 Mar 2025PDF
- Quarterly Report — 31 Mar 2025PDF
Sourced from official PSX financial-report submissions.
Recent Announcements
Latest company filings as reported on PSX
Filings and disclosures from the PSX announcement feed
- 02 Nov 2026Financial Results
- 27 Oct 2026Board Meeting
- 05 Oct 2026Financial Results
- 05 Oct 2026Report
- 05 Oct 2026Report
- 05 Oct 2026General Meeting
- 05 Oct 2026General Meeting
- 02 Oct 2026Board MeetingBoard meeting in Progress
Peers in Pharmaceuticals
How the cohort is moving — same-sector stocks by market cap
LIVEN vs Pharmaceuticals sector median
| Metric | LIVEN | Sector median |
|---|---|---|
| P/E RatioShare price ÷ earnings per share — the price you pay for each rupee of annual profit. Compare within a sector.Read the full guide → | — | 12.5x |
| Dividend YieldTrailing-12-month cash dividends ÷ share price. A high yield can signal income — or a falling price.Read the full guide → | — | 2.8% |
| Return on EquityNet profit ÷ shareholders' equity — how hard the company works each rupee investors have put in.Read the full guide → | -3.2% | 16.9% |
| 1-Year Return | -53.0% | -20.5% |
| Market CapitalisationShare price × total shares — the company's full market value, and the basis for index weightings.Read the full guide → | Rs 3.30B | Rs 14.93B |
Pharmaceuticals · sector heat
Why Choose BSL as Your PSX Broker?
Bhayani Securities is an SECP-licensed stock broker in Pakistan and PSX TREC holder with over two decades in the market. Investors get live prices, research and support in one account.
- Retail Trading
Open a PSX trading account with secure market access and research support.
- Online Trading
Trade on the BSL app with real-time PSX data and portfolio monitoring.
- Margin Financing
Borrow to trade larger positions and increase your buying power.
- Research Reports
Market insights, stock analysis and investing guides from BSL.
- Institutional Services
Research-driven execution, market insights and corporate access for institutions.
- High Net Worth Services
A dedicated senior dealer and preferential rates for portfolios above PKR 2.5 million.
- Trading APIs
Full PSX data, live level-2 market data and sandbox order execution through BSL.
- Roshan Digital Account
Invest in the PSX remotely as an overseas Pakistani.
- Sahulat Account
Start investing with minimal documentation and a fast setup.
- Minor Accounts
Invest for your children and build long-term wealth early.
Frequently Asked Questions
The most common questions investors ask about LIVEN
LIVEN last traded at Rs 29.11, down 4.84% on the day, within a 52-week range of Rs 27.82–70.68. Prices on this page refresh every 15 minutes during market hours; log in to BSL for live quotes.
Liven Pharma Limited was incorporated in Pakistan as a private Limited Company on October 21, 1991 and was converted into a public limited company on April 30, 1992 under the Companies Ordinance, 1984 (Repealed with the enactment of the Co… See About the Company on this page for the full profile, management, and corporate information.
LIVEN has not declared a cash dividend in the recent PSX record — some companies reinvest earnings instead; see the Financials section. For income ideas, browse the highest dividend yield stocks on PSX.
No upcoming payout is announced yet. The most recent was a 21.496% rights issue with book closure from 27 Nov 2025. New announcements appear on this page and on the PSX ex-dates calendar.
Yes — Liven Pharma Limited is on the PSX's Shariah-compliant (KMI All Shares) list. Browse all Shariah-compliant PSX stocks.
A side-by-side comparison with the Pharmaceuticals sector median — valuation, yield, and returns — is in the Peers section, or explore the Pharmaceuticals sector page.
Annual reports for FY2026 are linked under Reports & Filings in the About section of this page, sourced from official PSX submissions.
Open a BSL trading account, fund it, and place your LIVEN order on the Pakistan Stock Exchange — account opening takes minutes online, with PSX execution, research, and concierge support included.
Quotes and metrics refresh on a regular cadence through the trading day and after the close. For streaming real-time PSX prices and order placement, log in to your BSL account.
Ready to invest in LIVEN?
Open a BSL trading account in under 10 minutes
Buy and sell LIVEN and every other PSX-listed stock with low commissions, real-time data, and a concierge research desk backing every trade.